Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 5/20 | 0.47 |
| ▸ | SRC | P12931 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 5/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.36 |
| ▸ | GAK | O14976 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2125796 | 0.94 | PRKCQ (0.43) | PRKCQSRCEGFRERBB2CSNK2A1 | |
| SCHEMBL2125028 | 0.94 | SRC (0.45) | PRKCQSRCEGFRERBB2CSNK2A1 | |
| SCHEMBL2126290 | 0.90 | CSNK2A1 (0.43) | PRKCQSRCEGFRERBB2CSNK2A1 | |
| SCHEMBL2123031 | 0.89 | PRKCQ (0.40) | PRKCQSRCEGFRERBB2CSNK2A1 | |
| SCHEMBL2123111 | 0.89 | CSNK2A1 (0.47) | PRKCQSRCEGFRERBB2CSNK2A1 | |
| SCHEMBL2124727 | 0.88 | SRC (0.44) | PRKCQSRCEGFRCSNK2A1GAK | |
| SCHEMBL2125204 | 0.88 | CSNK2A1 (0.40) | PRKCQSRCEGFRERBB2CSNK2A1 | |
| SCHEMBL2122015 | 0.88 | CSNK2A1 (0.40) | PRKCQSRCEGFRERBB2CSNK2A1 | |
| SCHEMBL2126571 | 0.88 | CSNK2A1 (0.38) | PRKCQSRCEGFRERBB2CSNK2A1 | |
| SCHEMBL2125785 | 0.87 | EGFR (0.43) | PRKCQSRCEGFRERBB2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443123-B1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | claimed |
| US-8377945-B2 | Small molecule inhibitors of spleen tyrosine kinase (SYK) | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | claimed |
| EP-2443123-A2 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | Rigel Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | claimed |
| WO-2010147898-A2 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | claimed |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | MIDCAP FINANCIAL TRUST | 2010-12-16 | — | — | US | claimed |
| EP-2827890-B1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | UNIV QUEENSLAND (AU) | 2019-08-28 | — | — | EP | disclosed |
| EP-2443123-B1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-8377945-B2 | Small molecule inhibitors of spleen tyrosine kinase (SYK) | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2443123-A2 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | Rigel Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010147898-A2 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | MIDCAP FINANCIAL TRUST | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | SYK, BTK, LCK | PRKCQ 112/4885SRC 9/4885EGFR 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.